Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Major Wholesalers' 1st-half Sales Unexpectedly Good
November 11, 2002
-
ARCHIVE Meiji Seika, Bayer to Comarket Bayclear Plus
November 11, 2002
-
ARCHIVE Freund: Sales Up 1.9%, Operating Profits Down 41.2%
November 11, 2002
-
ARCHIVE GSK, Block Drug Company (Japan) Integrated on November 1
November 11, 2002
-
ARCHIVE Health Minister Determines to Set Up Better Healthcare System
November 11, 2002
-
ARCHIVE Kuraya Sanseido Takes Over OTC Business from Heisei Yakuhin
November 11, 2002
-
ARCHIVE Korosho to Prepare Comprehensive GL for Clinical Trials
November 11, 2002
-
ARCHIVE Council to Issue Supplements QC Verification Seals
November 11, 2002
-
ARCHIVE Dear-Doctor Letter for Edaravone Issued
November 11, 2002
-
ARCHIVE BD Places Great Importance on Social Contribution: President Cohen
November 11, 2002
-
ARCHIVE Revision of Precaution for 7 Drugs Including Famotidine Instructed
November 11, 2002
-
ARCHIVE Nippon Chemiphar to Comarket Allergy Test System with Wako Pure Chemical
November 11, 2002
-
ARCHIVE Eiken: FY2002 Profit Forecasts Revised Downward
November 4, 2002
-
ARCHIVE Shionogi Licenses Patents on BNP to Kyowa Medex
November 4, 2002
-
ARCHIVE MEET THE LEADERS (9)
November 4, 2002
-
ARCHIVE Roche to Launch Fully Automated Gene Detection Module in 2004
November 4, 2002
-
ARCHIVE REGULATORY BULLETIN
November 4, 2002
-
ARCHIVE DIAGNOSTIC NEWS IN BRIEF
November 4, 2002
-
ARCHIVE Kissei Licenses Novel Antidiabetic Agent to GSK
November 4, 2002
-
ARCHIVE NEW PRODUCTS
November 4, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…